The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes an identifiable piece of new business activity that has already started contributing partway through the reported period or is starting right now, and that the reported results captured only a partial early slice, with fuller run-rate arriving over next few quarters as a matter of timing. Let's examine the transcript. The call is for Q4 and fiscal year end 2023 (ended June 30, 2023). Management discusses several programs. Key candidates: Vyleesi, PL9643 (dry eye), PL8177 (ulcerative colitis), PL9588 (glaucoma), erectile dysfunction combination, etc. We need to find a specific new business activity that is already live or just going live, and that the reported period caught only part of it, and the fuller contribution is a timing matter. Look for phrases like "recently began", "just going live", "we have completed enrollment", "we are planning to initiate", etc. The transcript mentions: - Vyleesi: commercial product, growth, but that's ongoing, not new. - PL9643: MELODY-1 Phase III fully enrolled, data by year-end. That's a clinical trial, not revenue-generating business activity. - PL8177: Phase II in ulcerative colitis, on track to complete enrollment by year-end, interim data as early as year-end. Again, clinical trial. - PL9588: glaucoma, preclinical, regulatory discussions initiated. - Erectile dysfunction combination: "we are planning to initiate clinical programs as early as the end of this year." That's planned, not started. - UpScriptHealth partnership: "Palatin entered into a strategic partnership with UpScriptHealth... and we anticipate the reach for Vyleesi from an awareness standpoint will be increasing over the coming quarters." This is a partnership that was entered into, but is it already contributing? It says "entered into" and anticipates reach increasing. But does it describe actual revenue or activity already started? It's about awareness, not necessarily revenue. Also, it's not clear that the reported period caught only part of it. The partnership might be new, but the transcript doesn't say that it started mid-period or that results include only a partial slice. It says "we anticipate the reach... will be increasing over the coming quarters." That's forward-looking, not a statement that it already started contributing. - Fosun Pharma: reported first sale in Hainan Province of China.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| WHF | WhiteHorse Finance | Q1 2022 | 2022-05-10 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
SHOO · Q1 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the Schwartz & Benjamin acquisition as a new contributor that began delivering sales in the reported Q1 period ($14 million, slightly above plan), with the results capturing only its early partial slice. Management explicitly notes that the full-quarter impact will arrive in subsequent quarters (dragging gross margin more going forward), 2017 will be breakeven-to-EPS, and meaningful profit contribution starts in 2018—making the fuller run-rate a pure timing matter of integration and ramp rather than any further winning. This meets all three criteria. (Madden NYC and SM Europe are also new launches/JVs with early/modest contributions and growth ahead, but Schwartz & Benjamin is the clearest fit for the exact timing story.) NO for the other items because they are either not yet live (China JV), not described as partial/early-slice (SM Europe international growth), or not framed as timing-driven ramp (Madden NYC modest contribution is positive but 2018+ profit is more about execution than pure timing). The answer is YES.
AFL · Q2 2023 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the WINGS cancer insurance product launch in Japan Post (early April, during Q2) as a new, nameable contributor that began transacting mid-period. Management explicitly states it was the "majority contributor" to the 60% cancer sales increase in Q2 versus 2022, 26.6% overall sales premium growth, and notes the reported results captured only an early slice because "right when you launch the product, you'll have an immediate jump in sales in the early months followed by a calming down" with "still much more runway...
PDCO · Q3 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes Heartland Dental as a new customer relationship that began contributing in January (during the reported Q3 period), with the rollout completed on schedule and the business now "getting close to being fully operational." Management explicitly notes that this was "not a significant contributor to consumable sales in the third quarter" — confirming the reported results captured only a partial, early slice — while highlighting the "outstanding start" and excitement for further growth as the relationship scales.